Attenuating Diabetic Vascular and Neuronal Defects by Targeting P2rx7

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Diabetic retinopathy involves retinal vascular and neuronal damage.
• Neuroglial network defects may precede vascular lesions in diabetic retinopathy.
• Targeting early neurodegeneration could prevent diabetic retinopathy progression.

Purpose of the Study:

• To investigate the therapeutic potential of lamivudine (3TC) in a mouse model of diabetic retinopathy.
• To determine if 3TC, a P2rx7 inhibitor, can attenuate both neuronal and vascular pathology.

Main Methods:

• Assessed P2rx7 expression in diabetic mouse retinas.
• Evaluated the effect of 3TC treatment on retinal vascular and neuronal integrity.
• Measured electroretinogram (ERG) parameters (a- and b-wave, oscillatory potentials).
• Quantified GABAergic amacrine cells and synaptophysin-positive areas.

Main Results:

• P2rx7 expression was elevated in diabetic mouse retinas.
• 3TC treatment protected against acellular capillary formation in diabetic mice.
• 3TC preserved neuroglial function, indicated by improved ERG amplitudes.
• 3TC treatment increased the number of GABAergic amacrine cells and synaptophysin-positive area.

Conclusions:

• Lamivudine (3TC) demonstrates therapeutic potential for diabetic retinopathy.
• 3TC effectively targets both neuronal and vascular pathologies associated with diabetes.
• Inhibiting P2rx7 with 3TC may offer a novel treatment strategy for early diabetic retinopathy.